322 related articles for article (PubMed ID: 34664244)
21. Pericyte in Oral Squamous Cell Carcinoma: A Systematic Review.
Valle IB; Schuch LF; da Silva JM; Gala-García A; Diniz IMA; Birbrair A; Abreu LG; Silva TA
Head Neck Pathol; 2020 Dec; 14(4):1080-1091. PubMed ID: 32506378
[TBL] [Abstract][Full Text] [Related]
22. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
23. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche.
Díaz-Flores L; Gutiérrez R; Madrid JF; Varela H; Valladares F; Acosta E; Martín-Vasallo P; Díaz-Flores L
Histol Histopathol; 2009 Jul; 24(7):909-69. PubMed ID: 19475537
[TBL] [Abstract][Full Text] [Related]
24. The complex mural cell: pericyte function in health and disease.
van Dijk CG; Nieuweboer FE; Pei JY; Xu YJ; Burgisser P; van Mulligen E; el Azzouzi H; Duncker DJ; Verhaar MC; Cheng C
Int J Cardiol; 2015; 190():75-89. PubMed ID: 25918055
[TBL] [Abstract][Full Text] [Related]
25. Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation.
Darden J; Payne LB; Zhao H; Chappell JC
Angiogenesis; 2019 Feb; 22(1):167-183. PubMed ID: 30238211
[TBL] [Abstract][Full Text] [Related]
26. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.
Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM
Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901
[TBL] [Abstract][Full Text] [Related]
27. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
28. Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage.
Miljkovic-Licina M; Hammel P; Garrido-Urbani S; Lee BP; Meguenani M; Chaabane C; Bochaton-Piallat ML; Imhof BA
Mol Cancer Ther; 2012 Dec; 11(12):2588-99. PubMed ID: 23002094
[TBL] [Abstract][Full Text] [Related]
29. Pericyte-fibroblast transition promotes tumor growth and metastasis.
Hosaka K; Yang Y; Seki T; Fischer C; Dubey O; Fredlund E; Hartman J; Religa P; Morikawa H; Ishii Y; Sasahara M; Larsson O; Cossu G; Cao R; Lim S; Cao Y
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5618-27. PubMed ID: 27608497
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
[TBL] [Abstract][Full Text] [Related]
31. The NG2 Proteoglycan in Pericyte Biology.
Stallcup WB
Adv Exp Med Biol; 2018; 1109():5-19. PubMed ID: 30523586
[TBL] [Abstract][Full Text] [Related]
32. RET mutation and increased angiogenesis in medullary thyroid carcinomas.
Verrienti A; Tallini G; Colato C; Boichard A; Checquolo S; Pecce V; Sponziello M; Rosignolo F; de Biase D; Rhoden K; Casadei GP; Russo D; Visani M; Acquaviva G; Ferdeghini M; Filetti S; Durante C
Endocr Relat Cancer; 2016 Aug; 23(8):665-76. PubMed ID: 27402614
[TBL] [Abstract][Full Text] [Related]
33. Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells.
Hong J; Tobin NP; Rundqvist H; Li T; Lavergne M; García-Ibáñez Y; Qin H; Paulsson J; Zeitelhofer M; Adzemovic MZ; Nilsson I; Roswall P; Hartman J; Johnson RS; Östman A; Bergh J; Poljakovic M; Genové G
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26296362
[TBL] [Abstract][Full Text] [Related]
34. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.
Sadow PM; Priolo C; Nanni S; Karreth FA; Duquette M; Martinelli R; Husain A; Clohessy J; Kutzner H; Mentzel T; Carman CV; Farsetti A; Henske EP; Palescandolo E; Macconaill LE; Chung S; Fadda G; Lombardi CP; De Angelis AM; Durante O; Parker JA; Pontecorvi A; Dvorak HF; Fletcher C; Pandolfi PP; Lawler J; Nucera C
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25063326
[TBL] [Abstract][Full Text] [Related]
35. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.
Thijssen VL; Paulis YW; Nowak-Sliwinska P; Deumelandt KL; Hosaka K; Soetekouw PM; Cimpean AM; Raica M; Pauwels P; van den Oord JJ; Tjan-Heijnen VC; Hendrix MJ; Heldin CH; Cao Y; Griffioen AW
J Pathol; 2018 Dec; 246(4):447-458. PubMed ID: 30101525
[TBL] [Abstract][Full Text] [Related]
36. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
37. Screening assay for blood vessel maturation inhibitors.
Fu C; van der Zwan A; Gerber S; Van Den Berg S; No E; Wang WC; Sheibani N; Carducci MA; Kachhap S; Hammers HJ
Biochem Biophys Res Commun; 2013 Aug; 438(2):364-9. PubMed ID: 23892038
[TBL] [Abstract][Full Text] [Related]
38. Pericyte Biology: Development, Homeostasis, and Disease.
Birbrair A
Adv Exp Med Biol; 2018; 1109():1-3. PubMed ID: 30523585
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression.
Lees DM; Reynolds LE; Pedrosa AR; Roy-Luzarraga M; Hodivala-Dilke KM
Angiogenesis; 2021 Aug; 24(3):471-482. PubMed ID: 33730293
[TBL] [Abstract][Full Text] [Related]
40. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
